Molecular Profile | Unknown unknown |
Therapy | JNJ-40346527 |
Indication/Tumor Type | Hodgkin's lymphoma |
Response Type | not applicable |
Create By | spatt |
Update By | smockus |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | Unknown unknown | Hodgkin's lymphoma | not applicable | JNJ-40346527 | Phase II | Actionable | In a Phase II/III clinical trial, JNJ-40346527 demonstrated safety some efficacy, with complete response in 5.0% (1/20), partial response in 5.0% (1/20), and stable disease in 55.0% (11/20) of patients with refractory Hodgkin's lymphoma (PMID: 25628399). | 25628399 |
---|
PubMed Id | Reference Title | Details |
---|---|---|
(25628399) | An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma. | Full reference... |